

Pathophysiology of Dupuytren's Contracture

Submission date 11/08/2010	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 11/08/2010	Overall study status Completed	☐ Statistical analysis plan
		☐ Results
Last Edited 18/04/2017	Condition category Musculoskeletal Diseases	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Liaquat Suleman-Verjee

Contact details

Imperial College London
Kennedy Institute of Rheumatology Division
65 Aspenlea Road
London
United Kingdom
W6 8LH

Additional identifiers

Protocol serial number

6585

Study information

Scientific Title

Pathophysiology of Dupuytren's Contracture

Study objectives

Dupuytren's disease is a common inheritable disorder, mainly affecting the hand. The digits develop progressive flexion contractures and hand function is significantly impaired. The current mainstay of treatment is surgical excision of the affected tissues but recurrence following

excision is seen in approximately 40% of patients. Replacing the palmar skin with grafts obtained from a non-palmar site on the body virtually abolishes recurrence. Based on this well-established surgical observation, we have developed a novel in vitro model that replicates these interactions between skin cells and the contractile cells responsible for Dupuytren's disease. We have also identified a molecule (tenascin-C) that may control the signalling between these cell types.

Ethics approval required

Old ethics approval format

Ethics approval(s)

MREC approved, ref: 06/Q0403/95

Study design

Multicentre non-randomised interventional treatment trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Generic Health Relevance and Cross Cutting Themes; Subtopic: Generic Health Relevance (all Subtopics); Disease: Surgery

Interventions

Elucidate the exact role of tenascin-C in Dupuytren's disease

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Develop candidate therapeutic target to provide non-surgical intervention to modulate the disease

Key secondary outcome(s))

Not provided at time of registration

Completion date

31/07/2011

Eligibility**Key inclusion criteria**

Not provided at time of registration

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

02/11/2006

Date of final enrolment

31/07/2011

Locations**Countries of recruitment**

United Kingdom

England

Study participating centre

Imperial College London

London

United Kingdom

W6 8LH

Sponsor information**Organisation**

Royal College of Surgeons of England (UK)

ROR

<https://ror.org/02qrg5a24>

Funder(s)

Funder type

Charity

Funder Name

Healing Foundation

Alternative Name(s)**Funding Body Type**

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration